TAF1 and ovarian endometrioid adenocarcinoma: To assess whether TAF1(2) bromodomain inhibition shows an additional effect in non-AML lines, compounds were also tested in ovarian endometrioid adenocarcinoma (IGROV1) and breast carcinoma (HDQP1, DU4475) cell lines.